Our study found that AR was widely highly expressed in HR + breast cancers, and the expression rates in HR + /HR- and HR + /HR- were 82.5% and 85.9%, respectively, while the expression rate in TNBC was only 34.6%. The gene discussed is AR; the disease is breast carcinoma.